Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia

NCT00780598 is registered in ClinicalTrials.gov with Chroma Therapeutics as lead sponsor.

NCT NCT00780598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00780598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia
Lead sponsor
Chroma Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
March 31, 2011
Enrollment
76 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml